Vinblastine plus prednisone versus cytarabine alone for LCH
Treatments studied
Part of Blood & lymphatic, Lungs & breathing clinical trials.
This phase 3 study compares two treatment plans for Langerhans cell histiocytosis (LCH): vinblastine plus prednisone versus cytarabine alone. It aims to find which approach works better and is safer for children and young adults with LCH that needs medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your child) must have LCH confirmed by biopsy (a tissue test).
- Age must be 0 to 21 years.
- Energy and ability to do daily activities must be fair or better (Karnofsky or Lansky score at least 50%).
- You can’t have had prior chemotherapy pills/infusions for LCH or other cancers (except limited steroid use for a short time).
- The LCH pattern can’t be only one skin or bone spot, unless it’s a higher-risk or special location that usually still needs systemic treatment.
- Kidney and liver blood tests must not be severely abnormal, and there must be no pregnancy or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, low-dose cytarabine and thalidomide, for adults with Langerhans cell histiocytosis (LCH) that has not been treated before with systemic therapy. The goal is to see if this treatment is safe and effective for people with LCH in multiple body areas or multiple spots in one system.
This trial is testing a new targeted pill (luvometinib) alone or with another drug (cytarabine) for people with Langerhans cell histiocytosis that needs whole-body treatment. The goal is to see if the new approach can shrink or control the disease.
This trial tests a study drug, FCN-159, for children with a rare blood/immune disease called Langerhans cell histiocytosis (LCH) that has not responded to standard treatment or has come back. The goal is to see if this drug can shrink the LCH lesions and help the child feel better.
This trial tests a new drug called Luvometinib added to a standard chemotherapy regimen for children with Langerhans cell histiocytosis that affects multiple parts of the body. The goal is to see if the combination works better than the standard treatment alone.
This trial tests a combination of two drugs for children and teens with Langerhans cell histiocytosis (LCH) that has not responded to standard treatments or has come back after treatment. The goal is to see if the drugs can shrink lesions and improve symptoms.
This trial studies a treatment approach for children and teens newly diagnosed with lymphoblastic lymphoma. It may help doctors choose therapies based on genetic risk information from lab testing done on tumor samples.
Hear when a new Langerhans Cell Histiocytosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.